You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
醫藥板塊受捧跑贏 康希諾、京東健康、平安好醫生及阿里健康漲8%-12%
Omicron新冠變種疫情於全球肆虐,尤其是歐洲及美國近期確診病例急增,美國疫苗股默克(MRK.US)及輝瑞(PFE.US)上周五逆升1.9%及1.6%。 本港醫藥板塊今早升幅遠超大市,尤其是藍籌阿里健康(00241.HK)由逾三年半低位連升第三天兼突破10天及20天線(6.67元),最高見7.16元,現報7.04元,急漲11.8%,為最強藍籌;同業京東健康(06618.HK)及平安好醫生(01833.HK)續升9%,分別高見62.75元及29.9元,股價升破20天線。 疫苗股康希諾生物-B(06185.HK)連升第二天兼一舉升破50天、10天及20天線(166.3-170元),最高見180.9元,現報174.7元,續漲8%;復星醫藥(02196.HK)三連彈,最高見33.8元,現報33.5元,續升4.4%。 康方生物-B(09926.HK)續彈逾3%曾高見30.1元;百濟神州(06160.HK)續彈3.6%曾高見141.9元。 信達生物(01801.HK)續彈4.5%報42元。藍籌藥明生物(02269.HK)續彈3.8%高見84.1元;藥明康德(02359.HK)三連彈,最高見126元,現報122.4元,續升3.7%。 藍籌石藥(01093.HK)及中生製藥(01177.HK)續漲近6%,分別高見9.43元及6.3元,股價升破百天線。此外,神威藥業(02877.HK)續升4.6%高見7.08元;威高股份(01066.HK)續升4.6%曾高見10.42元。四環醫藥(00460.HK)回升7.5%報1.58元,股價重越50天線。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account